Protara Therapeutics, Inc. (TARA) · Nov 6, 2026 · Earnings

Protara earnings beat, but STARBORN-1 slips into 2027

Beat — GAAP EPS $(0.35) vs approximately $(0.37) consensus

Protara’s third-quarter earnings beat the expected loss, but STARBORN-1 enrollment moved into early 2027 as cash declined and trials advance.

Protara is a clinical-stage biotech built around TARA-002 for bladder cancer and lymphatic malformations, with IV Choline Chloride as a second late-stage program. Before this filing, management was targeting several fourth-quarter 2026 milestones, including STARBORN-1 enrollment, ADVANCED-2 enrollment and THRIVE-3 interim data.

Q3 2026Q3 2025Consensus
Net loss (Income Statement)$(21.688)M$(13.258)M
Diluted loss per share (Income Statement)$(0.35)$(0.31)$(0.37)
R&D expense (Income Statement)$16.805M$9.591M
Cash and marketable securities (Balance Sheet)$143.081M

The quarter modestly beat the loss consensus, but the underlying burn worsened year over year. Protara posted a diluted loss of $0.35 per share versus a published consensus of approximately $(0.37), a small earnings beat. The more important operating signal is that net loss widened to $21.688 million from $13.258 million, while R&D spending rose to $16.805 million from $9.591 million. 〔0〕

The clearest setback is a delay to the lymphatic-malformation program. Management previously targeted completion of STARBORN-1 enrollment in the fourth quarter of 2026; the new filing moves that milestone to early first quarter 2027. That is not a thesis-breaking delay, but it pushes the next regulatory-enabling step later than the standing plan. 〔1〕

The rest of the near-term development calendar remains intact, with a new manufacturing commitment. Protara still expects to complete the BCG-Unresponsive bladder-cancer cohort by year-end and report THRIVE-3 interim results by year-end. It also agreed after quarter end to purchase manufacturing-related assets from its supply partner, bringing production capability in-house as it prepares for potential TARA-002 commercialization. 〔2〕

Liquidity is still substantial, but the runway is less comfortable than it looked after the prior quarter. Cash and marketable debt securities fell to approximately $143.1 million at September 30 from approximately $161.9 million at June 30, while quarterly net loss reached $21.7 million. The filing does not repeat the prior assertion that existing liquidity funds planned operations into 2028, so the financing picture is less explicitly supported here. 〔3〕

Bottom line: The earnings beat is minor; the more meaningful update is mixed execution, with most milestones on track but STARBORN-1 enrollment slipping into early 2027. The company is advancing its programs and manufacturing setup, yet doing so with rising losses and declining liquidity.

What to watch next

THRIVE-3 interim results, by year-end 2026

Original filing on SEC EDGAR

Protara earnings beat, but STARBORN-1 slips into 2027 | TARA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.